Skip to content
Open in App
Absci logo

Absci

web2

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therap...

Symbol · ABSI
Company profile

About

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNasdaqPrimary symbol: ABSI
Expert coverage

1 expert evaluated Absci.

Orbitrum research

Experts evaluating Absci

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment